1 July 2020 in International Journal of Dermatology
8 April 2019 in Dermatologic Therapy
14 August 2012 in Oncology Letters
ASAlejandro José Sastre-Heres
Alejandro José Sastre-Heres
MHMiguel Angel Calleja Hernandez
Miguel Angel Calleja Hernandez
+1
A retrospective cohort study was conducted to analyse the effectiveness of bevacizumab and irinotecan (BVZ/CPT-11) as a second-line treatment in patients with primary glioblastoma multiforme (GBM) in comparison with a control group that were not administered BVZ/CPT-11 at the first recurrence. The difference in overall survival (OS) between the two groups was used as a predictor of effectiveness. OS was calculated according to prognostic factors and gender. A total of 28 and 32 patients were enrolled in the BVZ/CPT-11 cohort and control group, respectively. The median OS was 17.94 months (95% CI, 14.91–20.96) in the BVZ/CPT-11 treatment cohort and 10.97 months (95% CI, 7.65–14.30) in the control cohort. The results obtained on the effectiveness of BVZ/CPT-11 treatment in patients with primary GBM are consistent with data from previous studies. No significant differences were identified in OS based on prognostic factors; therefore, the latter cannot be used to select patients who would incur the greatest benefits from BVZ/CPT-11 treatment.
16 August 2020 in The Journal of Clinical Hypertension
The Systolic Blood Pressure Intervention Trial (SPRINT), a large randomized controlled trial funded by the National Institutes of Health, randomized 9361 patients with hypertension over 50 years of age and at least one cardiovascular risk factor to intensive (SBP < 120 mm Hg) or standard (SBP < 140 mm Hg) blood pressure treatment. The trial found a significant reduction in primary cardiovascular and mortality outcomes in the intensive treatment group. We performed an IRB‐approved post hoc analysis of the SPRINT trial data, recently made available through the NEJM SPRINT Data Analysis Challenge. Our subgroup analysis stratified subjects by age (≥75 years vs. <75 years) and presence or absence of pre‐existing chronic kidney disease (CKD) or cardiovascular disease (CVD). We found that intensive blood pressure control was associated with a significantly lower rate of the primary CVD outcome and all‐cause mortality in subjects age <75 years with no prior CVD or CKD and in subjects age ≥75 years with pre‐existing CVD or CKD.
12 November 2020 in International Journal of Dermatology
GMGerardo Martínez‐García
+4
Background: Coronavirus disease 2019 (COVID‐19) is a systemic multi‐organ viral illness. Previous studies have found that many patients had a procoagulant state and/or severe hypoxemia with relatively well‐preserved lung mechanics. Mechanisms underlying the damage to vascular tissues are not well‐elucidated yet. Histological data in COVID‐19 patients are still limited and are mainly focused on post‐mortem analysis. Given that the skin is affected by COVID‐19 and the relative ease of its histological examination, we aimed to examine the histology of skin lesions in COVID‐19 patients to better understand the disease’s pathology.Methods: Five skin lesions from COVID‐19 adult patients were selected for a deep histological tissue examination.Results: A strong vasculopathic reaction pattern based on prominent vascular endothelial and myointimal cell growth was identified. Endothelial cell distortion generated vascular lumen obliteration and striking erythrocyte and serum extravasation. Significant deposition of C4d and C3 throughout the vascular cell wall was also identified. A regenerative epidermal hyperplasia with tissue structure preservation was also observed.Conclusions: COVID‐19 could comprise an obliterative microangiopathy consisting on endothelial and myointimal growth with complement activation. This mechanism, together with the increased vascular permeability identified, could contribute to obliteration of the vascular lumen and hemorrhage in COVID‐19. Thus, anticoagulation by itself could not completely reverse vascular lumen obliteration, with consequent increased risk of hemorrhage. Findings of this study could contribute to a better understanding of physiopathological mechanisms underlying COVID‐19 on living patients and could help further studies find potential targets for specific therapeutic interventions in severe cases.
15 July 2016 in Oncology Letters
ASAlejandro José Sastre-Heres
Alejandro José Sastre-Heres
The purpose of the present study was to calculate the cost-effectiveness of the inclusion of the bevacizumab (BVZ) + irinotecan (CPT-11) regimen in the second-line of treatment for primary glioblastoma multiforme. A retrospective cohort study with a control group was performed in which the cost-effectiveness of a course of chemotherapy was calculated based on survival time and the incremental cost between the two lines of treatment. A total of 77 patients were included, 36 of who formed the BVZ/CPT-11 cohort. The median survival time for the non-BVZ control cohort was 13.23 months [95% confidence interval (CI), 11.79–14.68], while for the BVZ/CPT-11 treatment cohort, the median survival time was 17.63 months (95% CI, 15.38–19.89). Overall, each year of life gained for each patient treated with BVZ/CPT-11 would cost €46,401.99. These results demonstrate the effectiveness of the BVZ/CPT-11 combination, but its incremental cost compared with other lines of treatment or the best care available does not appear to be acceptable for public health systems in the current situation of budgetary adjustments.